August 5, 2013
MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Sequester Impact on Biomedical Research - Every Voice Counts
The effects of the sequester on the research community are becoming increasingly apparent, so we must take the opportunity to speak up and remind our political leaders that the reduced funding is having detrimental effects on biomedical research progress.
Last week, an open letter from 185 university leaders, including CWRU President Barbara R. Snyder, in the Washington, DC newspaper Politico, urged President Barack Obama and Congress to restore funding for research and education. Today, a Plain Dealer article highlighted the research of Dr. Yu-Chung Yang, a recent recipient of a Bridge Grant from the American Society of Hematology. Concerned that reduced NIH funding means reduced progress in cancer research, ASH is now offering funds to researchers whose work is considered promising, but was not scored well enough to secure funding from the NIH. As Dr. Yang pointed out in the article, it is not just her research that will suffer, but also that of the future generation of scientists and researchers.
The above examples are but a step in the right direction. Calling attention to the importance of reinstating funding levels for the NIH is the responsibility of every member of the cancer center and its community. Please take the time to voice your concerns and personal examples of just how the sequester will have a negative effect on your research progress. Write a short note to members of the Ohio caucus to reiterate how important this issue is to each of us, to our region, and to our national priorities.
Contact Information for Ohio Senators and Representatives:
CASE CCC IN THE NEWS
CWRU Researcher Benefits from National Grant Program Created to Protect Hematology Work from Budget Cuts (video)
University Hospitals Seidman Cancer Center expands to Parma hospital
NCI Panel: Stop Calling Low-Risk Lesions 'Cancer'
Schiemann and Carlin Attempt to Further Understand Triple Negative Breast Cancers; Research Highlighted in Cancer Research Breaking Advances
Triple-negative breast cancers (TNBCs) are an unusually aggressive and metastatic form of breast cancer for which there are currently no FDA-approved treatments. Interestingly, TNBCs typically express robust levels of epidermal growth factor receptor (EGFR), whose clinical targeting has proven to be unremarkable for reasons that remain mysterious. A collaborative paper published in the Journal of Biological Chemistry by the Carlin and Schiemann laboratories identified an innovative mechanism that partially explains the ineffectiveness of EGFR inhibitors to alleviate TNBCs. Using a novel EGFR-driven model of TNBC development and metastatic progression, the authors found that primary tumor growth depends upon their ability to stimulate the proto-oncogene Stat3, an event that transpired through a Src-dependent EGFR signaling axis and could be inactivated by administration of EGFR antagonists. Importantly, inducing TNBCs to undergo an epithelial-mesenchymal transition (EMT) program not only enhanced their metastatic aggressiveness, but also switched the manner through which they activate Stat3 during metastasis. Indeed, post-EMT TNBCs relied upon fibronectin present in the tumor microenvironment to activate a β1 integrin:FAK/Pyk2:JAK2 signaling axis operant in stimulating Stat3 and their metastatic outgrowth. Unlike their pre-EMT counterparts, post-EMT TNBCs were insensitive to EGFR antagonists and instead acquired sensitivity to JAK2 and Stat3 inhibitors. Collectively, this study identified an important mechanism whereby TNBCs exploit EMT programs to bypass growth factor signaling pathways that are essential for tumor initiation in favor of tumor microenvironmental signals critical for their metastatic progression. Nikolas Balanis, Michael Wendt, Barbara Schiemann, John Wang, Bill Schiemann, and Cathleen Carlin contributed to this publication.
Team from the Center for Computational Imaging and Personalized Diagnostics Receives Coulter Translational Award
Drs. Pallavi Tiwari and Anant Madabhushi have been awarded a Coulter Translational Award for their project, NeuroRadVision: Image based risk assessment for presence of recurrent tumor or radiation effects on MRI. The project involves developing novel image analytic approaches to distinguish radiation effects from recurrent brain tumors, a significant clinical problem in the management of brain tumor patients. Clinical collaborators on this project include Drs. Lisa Rogers, Leo Wolansky, and Andrew Sloan.
Avon Safety Net Program
The Avon Safety Net Program supports institutions and organizations that have traditionally cared for uninsured, at-risk, low-income and minority patients to further our commitment of enabling medically underserved women and men to access post-screening diagnostics and care.
Leukemia & Lymphoma Society (LLS) Career Development Program (CDP)
The Leukemia & Lymphoma Society Career Development Program offers the opportunity for researchers to take part in basic, clinical or translational research to help treat leukemia, lymphoma and myeloma.
Special Chalk Talk: Division of Hematology and Oncology
Immunology Invited Speaker Seminar Series
DNA Damage/Repair Speaker Series
Hematology and Oncology Division Research Conference
Cancer Center Research in Progress will resume in September
Taussig Cancer Institute Grand Rounds will resume in September
Hematology and Oncology Fellows Conference
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
ADDITIONAL UPCOMING SEMINARS & EVENTS
MSC 2013: Adult Stem Cell Therapy & Regenerative Medicine
Molecular Genetics Guest Speaker
National GvHD Health Symposium
PREVIOUSLY ANNOUNCED OPPORTUNITIES
American Cancer Society Institutional Research Grant (IRG) Awards
AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
NIH BULLETIN – Notices and Funding Opportunities
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.